<

RENTSCHLER BIOPHARMA SE EQS-News: Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

Transparency directive : regulatory news

11/07/2024 14:00

EQS-News: Rentschler Biopharma SE / Key word(s): Expansion
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

11.07.2024 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

  • Largest expansion in company’s 150+-year history opens
  • Major client project already underway; new clients actively being onboarded

Laupheim, Germany and Milford (MA), USA, July 11, 2024 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully operational. The company has a major project underway at the new line, with several additional projects in the pipeline, and continues to welcome new projects and clients.

The new production line is the largest investment in Rentschler Biopharma’s more than 150-year history. The groundbreaking took place in August 2021, during the COVID-19 pandemic, and the first engineering run of a 2,000L batch has been recently completed. With this, the line is now fully up and running. The multi-product facility, which doubles Rentschler Biopharma’s global cGMP capacity, is focusing mainly on commercial production of highly complex molecules. The original Milford site went from a single-product commercial facility to producing multiple products in an up to 500L bioreactor setup. The new production line has added 22,000 square feet of manufacturing cleanroom space and houses four new 2,000L single-use bioreactors, bringing the total of production lines at the site up to three.

Benedikt von Braunmühl, CEO of Rentschler Biopharma SE, commented: “As a fifth-generation, family-owned company, we stand at the forefront of manufacturing innovative therapies for patients with serious and rare diseases worldwide. The completion of our new, state-of-the-art production line is an important milestone for our company and emphasizes Rentschler Biopharma’s strong capabilities in the U.S. Our clients are our partners, and we are working with them to empower tomorrow’s therapies today. Indeed, in 2023, Rentschler Biopharma was proud to contribute to nearly 25% of the biopharmaceuticals approved by the U.S. FDA. I would like to thank our teams on both sides of the Atlantic who worked tirelessly together to get this important facility online.”

Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S.  noted: “Our new line is vital to growing our business and effectively serving the U.S. market, and I am excited about bringing in new clients as well as expanding our support of existing ones with a reliability they can trust.

I also would like to extend my gratitude to the entire team for their strong support in getting this important new production line up and running. We are embarking on a new stage in our long and successful history and are poised to tackle the most complex challenges in biopharmaceutical development and manufacturing. In light of evolving industry legislation, we remain committed to supporting our clients responsibly and contributing positively to both national interests and global health advancements.”

Rentschler Biopharma acquired the Milford site in 2019. Since then, the company has transformed the facility into a multi-product manufacturing site, expanding it from 93,000 square feet to 138,000 square feet in total. Earlier this year, the company received the Gold Award for the Central Massachusetts region in the 20th Annual Team Massachusetts Economic Impact Awards for its significant contributions to job growth, facility expansion, investment, and community engagement. 

 

 About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. A third site, located in Stevenage, UK, is dedicated to advanced therapies. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability. For further information about the company, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn.

 

Contact:
Rentschler Biopharma SE

Dr. Latika Bhonsle-Deeng
Head of Communications
Phone: +49-7392-701-874
communications@rentschler-biopharma.com

 Media inquiries:

MC Services AG
Eva Bauer
Phone: +49-89-210228-0
rentschler@mc-services.eu
U.S.
Laurie Doyle
Phone: +1-339-832-0752

For high-resolution images, please contact communications@rentschler-biopharma.com.



11.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1943711  11.07.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1943711&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6


Other stories

21/07/2024 21:52
21/07/2024 13:56
21/07/2024 18:10
21/07/2024 15:16
21/07/2024 16:57
21/07/2024 09:20
21/07/2024 19:58
21/07/2024 18:43
21/07/2024 20:12
21/07/2024 20:20
21/07/2024 15:07
21/07/2024 12:29
21/07/2024 10:04
21/07/2024 12:19
21/07/2024 15:46
21/07/2024 11:12
21/07/2024 13:00
21/07/2024 14:28
21/07/2024 15:31
21/07/2024 18:25
21/07/2024 16:18
21/07/2024 15:37
21/07/2024 10:45
21/07/2024 14:12
21/07/2024 18:52
21/07/2024 09:50
21/07/2024 22:00
21/07/2024 18:55
21/07/2024 21:28
21/07/2024 19:45
21/07/2024 18:28
21/07/2024 02:21
21/07/2024 11:35
20/07/2024 04:00
21/07/2024 19:19
21/07/2024 14:25
20/07/2024 06:00
20/07/2024 10:15